Nausea & vomiting in pregnancy (NVP), commonly known as "morning sickness", affects 50-90% of pregnant women.
In most women, the condition manifests between the 4th-7th week after last menstrual period and resolves by the 16th week of gestation.
It manifests in a spectrum of severity from mild nausea to very rare life-threatening symptoms.
The etiology is multifactorial.
The pregnant woman's sense of well-being and her daily activities are greatly affected by nausea and vomiting; the physical and emotional impact often leads to anxiety and worry about the effect of the symptoms on the fetus and reduced job efficiency.
Drug Information
Shine Neurobine
vitamin B1 mononitrate + vitamin B12 + vitamin B6 ...

Indication: Mononeuropathies & polyneuropathies eg, diabetic, alcoholic & toxic neuropathies. Neuritis & neura...

Indication: Prevention & treatment of nausea, vomiting or vertigo associated w/ motion sickness & other vestibular...

vitamin B1 mononitrate + vitamin B12 + vitamin B6

Indication: Mono- & polyneuropathies (eg, diabetic, alcoholic & toxic neuropathies). Neuritis & neuralgia. Vit...

cyanocobalamin + pyridoxine hydrochloride + thiami...

Indication: Mono- & polyneuropathies, deficiency or raised vit B1, B6 & B12 requi...

vitamin B1 + vitamin B12 + vitamin B6
B Complex Upha
nicotinamide + vitamin B1 + vitamin B12 + vitamin ...
mecobalamin + vitamin B1 + vitamin B6
Becolim 100
D-panthenol + niacinamide + vitamin B1 + vitamin B...
2  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2019
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Roshini Claire Anthony, 6 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

6 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.